Asses Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal
cancer who receive oxaliplatin-containing chemotherapy and bevacizumab